ASR Vermogensbeheer N.V. 13F: Adds $36M to Stryker (SYK) Stake

ASR Vermogensbeheer N.V. has increased its stake in Stryker Corporation (NYSE: SYK) by 129,793 shares, bringing its total ownership to 131,524 shares valued at about $36.2 million, as disclosed in a filing on October 16, 2026.

What Changed in ASR Vermogensbeheer N.V.'s Stryker Position

The firm added to its existing position, which now represents a 7,498.15% increase in share count since the last reported holdings. This move indicates ASR Vermogensbeheer's growing confidence in Stryker's potential in the healthcare sector.

Other Institutional Activity in Stryker

Several other institutional investors have also adjusted their holdings in Stryker. Blackrock Inc. reduced its stake by 187,697 shares, ending with 27,414,742 shares valued at approximately $8.08 billion. In contrast, Vanguard Capital Management LLC increased its position by 154,439 shares, bringing its total to 22,536,843 shares worth about $6.64 billion. JPMorgan Chase & Co. saw an increase of 1,664,175 shares, now holding 17,260,943 shares valued at $5.09 billion, while State Street Corporation added 182,664 shares, raising its holdings to 15,532,565 shares worth approximately $4.58 billion.

Stryker Corporation Stock Up 4.4%

Stryker shares have recently traded around $294.09, which is 25.1% below their 52-week high of $392.55. The stock is currently under its 50-day moving average of $300.80 and its 200-day moving average of $326.94. This positioning may attract investors looking for potential recovery opportunities.

Recent Earnings

Stryker reported a trailing twelve-month revenue of approximately $25.8 billion and earnings per share of $9.65. The company's revenue growth year-over-year stands at 9.4%, with a net margin of 14.4%. The next earnings report is expected on October 29, 2026.

Insider Buying and Selling at Stryker Corporation

Recent insider activity included several significant sales. Officer Robert S. Fletcher sold 4,544 shares valued at about $1,394,409 on May 28, 2026. Debra King, another officer, sold 826 shares for approximately $277,787 on August 18, 2026. Director Ronda E. Stryker sold 350,000 shares, valued at around $117.8 million, on August 19, 2026. These transactions could reflect broader strategies and market conditions rather than negative sentiments about the company's performance.

Analysts Set New Price Targets

On October 7, 2026, Barclays initiated coverage with an 'Overweight' rating and set a price target of $375. Prior to that, several firms maintained their ratings, including Stifel, which maintained a 'Buy' rating but lowered its target from $360 to $330, and Truist Securities, which kept a 'Hold' rating and reduced its target from $340 to $310. Overall, analysts recommend a 'Buy' on Stryker with a mean price target of $362.62 based on 26 opinions.

About Stryker Corporation

Stryker Corporation is a leading medical technology company that designs and manufactures a variety of products in the medical devices sector. It operates through various segments, including MedSurg and Neurotechnology, and Orthopaedics. The firm's recent stake increase by ASR Vermogensbeheer highlights continued investor interest in its innovative solutions and growth potential in the healthcare market.

Bottom Line

Watch for Stryker's upcoming earnings announcement on October 29, 2026, to gauge its performance. ASR Vermogensbeheer's filing reflects holdings as of the reporting period and may not represent its current position in Stryker.